Venkatraman, Navin <br/><br/>
Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™.  [electronic resource] 

 -  Vaccine  10 2017 
 - 6208-6217 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1873-2518 
<br/><br/><label>Standard No.: </label>10.1016/j.vaccine.2017.09.028  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenoviridae--immunology<br/>Adjuvants, Immunologic--administration & dosage<br/>Adolescent<br/>Adult<br/>Antibodies, Protozoan--immunology<br/>Enzyme-Linked Immunospot Assay--methods<br/>Epitopes--adverse effects<br/>Female<br/>Genetic Vectors--adverse effects<br/>Humans<br/>Immunity, Cellular--immunology<br/>Immunity, Humoral--immunology<br/>Immunization, Secondary--adverse effects<br/>Immunogenicity, Vaccine--immunology<br/>Immunoglobulin G--immunology<br/>Malaria Vaccines--adverse effects<br/>Malaria, Falciparum--immunology<br/>Male<br/>Middle Aged<br/>Nanoparticles--adverse effects<br/>Protozoan Proteins--immunology<br/>Saponins--adverse effects<br/>T-Lymphocytes--immunology<br/>Vaccination--adverse effects<br/>Vaccinia--immunology<br/>Young Adult